Successful treatment of MMP-9-expressing angiosarcoma with low-dose docetaxel and bisphosphonate

Case Reports in Dermatology

Volumn 4, Issue 1, 2012, Pages 5-9

  Ishibashi, Masaya ^a   Fujimura, Taku ^a   Hashimoto, Akira ^a   Haga, Takahiro ^a   Onami, Kaoru ^a   Tsukada, Akira ^a   Kambayashi, Yumi ^a   Hidaka, Takanori ^a   Furudate, Sadanori ^a   Shimada, Ryoko ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiosarcoma; Bisphosphonate; Docetaxel; MMP 9

Indexed keywords

DOCETAXEL; GELATINASE B; RISEDRONIC ACID;

AGED; ANGIOSARCOMA; ARTICLE; BODY SURFACE; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; LOW DRUG DOSE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SCALP; TREATMENT OUTCOME;

EID: 84860727591     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000335999     Document Type: Article

References (16)

1. Sasaki R, Soejima T, Kishi K, Imajo Y, Hirota S, Kamikonya N, Murakami M, Kawabe T, Ejima Y, Matsumoto A, Sugimura K: Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys 2002;15:1032-1040.
2. Ward JR, Feigenberg SJ, Mendenhall NP, Marcus RB, Mendenhall WM: Radiation therapy for angiosarcoma. Head Neck 2003;25:873-878.
3. Koontz BF, Miles EF, Rubio MA, Madden JF, Fisher SR, Scher RI, Brizel DM: Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head and Neck 2008;30:262-266.
4. Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer and Metastasis Rev 2004;23:101-117.
5. Murakami M, Sakai H, Kodama A, Yanai T, Mori T, Maruo K, Masegi T: Activation of matrix metalloproteinase (MMP)-2 by membrane type 1-MMP and abnormal immunolocalization of the basement membrane components laminin and type IV collagen in canine spontaneous hemangiosarcoma. Histol Histopathol 2009;24:437-446.
6. Takeuchi T, Iwasaki S, Miyazaki J, Nozaki Y, Takahashi M, Ono M, Saibara T, Furihata M: Matrix metalloproteinase-1 expressing in splenic angiosarcoma metastasizing to serous membrane. Int J Clin Exp Pathol 2010;3:634-639.
7. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishiori C: Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma. Cancer 2007;110:648-651.
8. Nagano T, Tai Y, Higashida Y, Fujiwara N, Oka M, Nishigori C: Docetaxel monotherapy for angiosarcoma in an elderly patient. Arch Dermatol 2007;43:1602-1603.
9. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR: Randomized phase II study of docetaxel versus doxorubicin in first and second line chemotherapy for locally advanced or metastatic soft tissue sarcoma in adults. J Clin Oncol 2000;18:2081-2086.
10. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-637.
11. Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S: A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010;20:318-325.
12. Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM: Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006;25:7260-7266.
13. Monhian N, Jewett BS, Baker SR, Varani J: Matrix metalloproteinase expression in normal skin associated with basal cell carcinoma and in distal skin from the same patients. Arch Facial Plast Surg 2005;7:238-243.
14. Rasheed H, Tolba Fawzi MM, Abdel-Halim MR, Eissa AM, Mohammed Salem N, Mahfouz S: Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides. Am J Dermatopathol 2010;32:162-169.
15. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-11446.
16. Fujimura T, Mahnke K, Enk AH: Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 2010;59:1-6.